Quest Diagnostics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DGX and other ETFs, options, and stocks.

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. 

CEO
James E. Davis
CEOJames E. Davis
Employees
57,000
Employees57,000
Headquarters
Secaucus, New Jersey
HeadquartersSecaucus, New Jersey
Founded
1967
Founded1967
Employees
57,000
Employees57,000

DGX Key Statistics

Market cap
23.17B
Market cap23.17B
Price-Earnings ratio
23.15
Price-Earnings ratio23.15
Dividend yield
1.55%
Dividend yield1.55%
Average volume
998.57K
Average volume998.57K
High today
$211.29
High today$211.29
Low today
$206.98
Low today$206.98
Open price
$211.29
Open price$211.29
Volume
223.96K
Volume223.96K
52 Week high
$213.50
52 Week high$213.50
52 Week low
$164.65
52 Week low$164.65

Stock Snapshot

With a market cap of 23.17B, Quest Diagnostics(DGX) trades at $209.32. The stock has a price-to-earnings ratio of 23.15 and currently yields dividends of 1.55%.

On 2026-06-29, Quest Diagnostics(DGX) stock moved within a range of $206.98 to $211.29. With shares now at $209.32, the stock is trading +1.1% above its intraday low and -0.9% below the session's peak.

Trading activity shows a volume of 223.96K, compared to an average daily volume of 998.57K.

Over the past 52 weeks, Quest Diagnostics(DGX) stock has traded between a high of $213.50 and a low of $164.65.

Over the past 52 weeks, Quest Diagnostics(DGX) stock has traded between a high of $213.50 and a low of $164.65.

DGX News

MarketWatch 3d
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch

...

Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Simply Wall St 4d
Did Nationwide Approval of Haystack MRD Liquid Biopsy Just Shift Quest Diagnostics' Investment Narrative?

In June 2026, Quest Diagnostics announced that New York State’s Clinical Laboratory Evaluation Program approved its Haystack MRD liquid biopsy test, allowing na...

Did Nationwide Approval of Haystack MRD Liquid Biopsy Just Shift Quest Diagnostics' Investment Narrative?
TipRanks 5d
Quest Diagnostics’ Haystack MRD test receives New York SDOH approval

Quest Diagnostics (DGX) announced that the New York State Department of Health’s, or NYSDOH, Clinical Laboratory Evaluation Program, or CLEP, has approved the c...

Analyst ratings

48%

of 21 ratings
Buy
47.6%
Hold
47.6%
Sell
4.8%

People also own

Based on the portfolios of people who own DGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.